Kymera Therapeutics, Inc.
US ˙ NasdaqGM ˙ US5015751044

SecurityKYMR / Kymera Therapeutics, Inc.
InstitutionState Street Corp
Latest Disclosed Ownership1,894,279 shares
Ownership 3.41%
State Street Corp ownership in KYMR / Kymera Therapeutics, Inc.

2024-01-23 - State Street Corp has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,894,279 shares of Kymera Therapeutics, Inc. (US:KYMR). This represents 3.41 percent ownership of the company. In their previous filing dated 2023-02-08 , State Street Corp had reported owning 2,846,221 shares, indicating a decrease of -33.45 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2024-01-23 2024-01-23 13G/A 2,846,221 1,894,279 -33.45 3.41 -34.30
2023-02-08 2023-02-08 13G 2,846,221 5.19

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F KYMERA THERAPEUTICS COM 501575104 2,389,767 179,930 8.14 199,044 15.76 0.0069
2026-02-13 2025-12-31 13F KYMERA THERAPEUTICS COM 501575104 2,209,837 190,383 9.43 171,947 50.43 0.0058
2025-11-14 2025-09-30 13F KYMERA THERAPEUTICS COM 501575104 2,019,454 465,023 29.92 114,301 68.50 0.0040
2025-08-14 2025-06-30 13F KYMERA THERAPEUTICS COM 501575104 1,554,431 -206,276 -11.72 67,835 40.77 0.0025
2025-05-15 2025-03-31 13F KYMERA THERAPEUTICS COM 501575104 1,760,707 71,918 4.26 48,191 -29.07 0.0020
2025-02-14 2024-12-31 13F KYMERA THERAPEUTICS COM 501575104 1,688,789 -39,355 -2.28 67,940 -16.94 0.0027
2024-11-14 2024-09-30 13F KYMERA THERAPEUTICS COM 501575104 1,728,144 -182,547 -9.55 81,793 43.41 0.0033
2024-08-14 2024-06-30 13F KYMERA THERAPEUTICS COM 501575104 1,910,691 -761,827 -28.51 57,034 -46.91 0.0025
2024-05-15 2024-03-31 13F KYMERA THERAPEUTICS COM 501575104 2,672,518 778,239 41.08 107,435 122.76 0.0048
2024-02-14 2023-12-31 13F KYMERA THERAPEUTICS COM 501575104 1,894,279 -91,607 -4.61 48,228 74.72 0.0023
2023-11-14 2023-09-30 13F KYMERA THERAPEUTICS COM 501575104 1,985,886 -634,423 -24.21 27,604 -54.18 0.0015
2023-08-14 2023-06-30 13F KYMERA THERAPEUTICS COM 501575104 2,620,309 -106,516 -3.91 60,241 -25.44 0.0032
2023-05-15 2023-03-31 13F KYMERA THERAPEUTICS COM 501575104 2,726,825 -119,396 -4.19 80,796 13.73 0.0046
2023-05-15 2022-12-31 13F/A-99 KYMERA THERAPEUTICS COM 501575104 2,846,221 160,817 5.99 71,042 21.52 0.0042
2023-05-15 2022-12-31 13F KYMERA THERAPEUTICS COM 501575104 2,846,221 160,817 71,042 0.0042
2022-11-15 2022-09-30 13F KYMERA THERAPEUTICS COM 501575104 2,685,404 -829,034 -23.59 58,461 -15.52 0.0037
2022-08-15 2022-06-30 13F KYMERA THERAPEUTICS COM 501575104 3,514,438 1,419,877 67.79 69,199 -21.93 0.0041
2022-05-16 2022-03-31 13F KYMERA THERAPEUTICS COM 501575104 2,094,561 452,799 27.58 88,642 -14.96 0.0044
2022-02-14 2021-12-31 13F KYMERA THERAPEUTICS COM 501575104 1,641,762 201,986 14.03 104,235 23.25 0.0049
2021-11-15 2021-09-30 13F KYMERA THERAPEUTICS COM 501575104 1,439,776 103,130 7.72 84,572 30.46 0.0045
2021-08-16 2021-06-30 13F KYMERA THERAPEUTICS COM 501575104 1,336,646 399,731 42.66 64,827 78.05 0.0034
2021-07-09 2021-03-31 13F/A-1 KYMERA THERAPEUTICS COM 501575104 936,915 776,370 483.58 36,409 265.77 0.0021
2021-05-17 2021-03-31 13F KYMERA THERAPEUTICS COM 501575104 936,915 776,370 36,409 0.0021
2021-02-16 2020-12-31 13F KYMERA THERAPEUTICS COM 501575104 160,545 160,545 9,954 0.0006
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.